Stakeholder forum to discuss post-market review of COPD medicines

Members of the respiratory community will meet in Sydney at the end of the month to discuss the ongoing post-market review of COPD medicines. The review was launched by the PBAC in 2015 following concerns about the multiple use of a number of new combinations available on the PBS, including long-acting muscarinic antagonist (LAMA)/LABA and ...